JACC WHITE PAPER
Combining Antiplatelet and Anticoagulant Therapies
David R. Holmes, Jr, MD*,*,
Dean J. Kereiakes, MD ,
Neal S. Kleiman, MD ,
David J. Moliterno, MD||,
Giuseppe Patti, MD¶ and
Cindy L. Grines, MD
* Mayo Clinic Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
The Christ Hospital Heart and Vascular Center/The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio
William Beaumont Hospital, Royal Oak, Michigan
Methodist DeBakey Heart and Vascular Center, Houston, Texas
|| Gill Heart Institute, University of Kentucky College of Medicine, Lexington, Kentucky
¶ Department of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Italy
Manuscript received December 27, 2008;
revised manuscript received March 19, 2009,
accepted March 24, 2009.
* Reprint requests and correspondence: Dr. David R. Holmes, Jr, Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55905 (Email: holmes.david{at}mayo.edu).
Antiplatelet therapy is the cornerstone for both primary and secondary prevention therapies for ischemic events resulting from coronary atherosclerotic disease. Dual antiplatelet therapy (aspirin plus a thienopyridine, usually clopidogrel) has assumed a central role in the treatment of acute coronary syndromes and after coronary stent deployment. In addition to antiplatelet therapy, anticoagulant therapy might be indicated for stroke prevention in a variety of conditions that include atrial fibrillation, profound left ventricular dysfunction, and after mechanical prosthetic heart valve replacement. For this reason, the use of triple antithrombotic therapy (a dual antiplatelet regimen plus warfarin) is expected to become more prominent, given an aging patient population. But although triple therapy can prevent both thromboembolism and stent thrombosis, it is also associated with significant bleeding hazards. Furthermore, when bleeding events do occur, the challenge of balancing the risk of stent thrombosis or stroke and the need for hemostasis requires considerable expertise. It is both prudent and timely to review treatment strategies that employ combinations of antiplatelet and anticoagulant therapies as well as strategies aimed at reducing bleeding risk in patients treated with these therapies.
Key Words: anticoagulant • antiplatelet • therapies
Related Article
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A24.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
D. P. Faxon, J. W. Eikelboom, P. B. Berger, D. R. Holmes Jr, D. L. Bhatt, D. J. Moliterno, R. C. Becker, and D. J. Angiolillo
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting: A North American Perspective: Executive Summary
Circ Cardiovasc Interv,
October 1, 2011;
4(5):
522 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ghattas, E. Shantsila, and G. Y. H. Lip
Antithrombotic therapy after percutaneous coronary intervention in anticoagulated patients: a fine balance between thrombosis and bleeding
Therapeutic Advances in Cardiovascular Disease,
February 1, 2011;
5(1):
5 - 9.
[PDF]
|
|
|
|
|
|
|
P. P. Singh, M. Singh, U. Bedi, J. Molnar, R. Arora, and S. Khosla
Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation
Therapeutic Advances in Cardiovascular Disease,
February 1, 2011;
5(1):
23 - 31.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Fisher and J. Loscalzo
The Perils of Combination Antithrombotic Therapy and Potential Resolutions
Stroke,
February 1, 2011;
42(2):
278 - 281.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fisher and J. Loscalzo
The Perils of Combination Antithrombotic Therapy and Potential Resolutions
Circulation,
January 25, 2011;
123(3):
232 - 235.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. S. Wann, A. B. Curtis, C. T. January, K. A. Ellenbogen, J. E. Lowe, N. A. M. Estes III, R. L. Page, M. D. Ezekowitz, D. J. Slotwiner, W. M. Jackman, et al.
2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
J. Am. Coll. Cardiol.,
January 11, 2011;
57(2):
223 - 242.
[Full Text]
[PDF]
|
|
|
|
|
|
|
2011 Writing Group Members, L. S. Wann, A. B. Curtis, C. T. January, K. A. Ellenbogen, J. E. Lowe, N. A. M. Estes III, R. L. Page, M. D. Ezekowitz, D. J. Slotwiner, et al.
2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation,
January 4, 2011;
123(1):
104 - 123.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. P. Alexander and E. D. Peterson
Minimizing the Risks of Anticoagulants and Platelet Inhibitors
Circulation,
May 4, 2010;
121(17):
1960 - 1970.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al.
Highlights of the Year in JACC 2009
J. Am. Coll. Cardiol.,
January 26, 2010;
55(4):
380 - 407.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Massberg, J. Mehilli, and A. Kastrati
Chapter 25 The role of bivalirudin in percutaneous coronary intervention
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
|
|
|
Interview